Literature DB >> 9856513

Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease.

D A O'Sullivan1, V E Torres, P A Gabow, S N Thibodeau, B F King, E J Bergstralh.   

Abstract

Recent experiments in cultured cyst epithelial cells from kidneys of patients with autosomal dominant polycystic kidney disease (ADPKD) have shown that the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) is present in the apical surface of these cells and mediates chloride (Cl-) and fluid secretion in vitro. To determine whether the presence of CF with the expression of mutated CFTR proteins modifies cyst formation in ADPKD, we studied a large family with both inherited diseases. ADPKD in this family is linked to PKD1. The family is composed of 26 members; 11 members with ADPKD, 4 members with CF, and 2 members with both diseases. Renal volumes measured by computerized tomography (CT), calculated creatinine clearances, and other clinical parameters in the family members with ADPKD and CF were compared with those in the family members with ADPKD alone, as well as to a large population of patients with ADPKD. The patients with CF and ADPKD, but not the CF heterozygote carriers with ADPKD, had less severe polycystic kidney and liver disease, as indicated by normal renal function; smaller renal volume, even when corrected for height and body surface area; and the absence of hypertension and liver cysts. These observations suggest that the coexistence of CF may reduce the severity of ADPKD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9856513     DOI: 10.1016/s0272-6386(98)70072-1

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  17 in total

1.  Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model.

Authors:  Lukmanee Tradtrantip; N D Sonawane; Wan Namkung; A S Verkman
Journal:  J Med Chem       Date:  2009-10-22       Impact factor: 7.446

Review 2.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

Review 3.  Determinants of renal disease variability in ADPKD.

Authors:  Peter C Harris; Sandro Rossetti
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

4.  Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease.

Authors:  David S Snyder; Lukmanee Tradtrantip; Chenjuan Yao; Mark J Kurth; A S Verkman
Journal:  J Med Chem       Date:  2011-07-12       Impact factor: 7.446

5.  Pharmacological reversal of renal cysts from secretion to absorption suggests a potential therapeutic strategy for managing autosomal dominant polycystic kidney disease.

Authors:  Murali K Yanda; Boyoung Cha; Cristina V Cebotaru; Liudmila Cebotaru
Journal:  J Biol Chem       Date:  2019-09-30       Impact factor: 5.157

Review 6.  Drug discovery for polycystic kidney disease.

Authors:  Ying Sun; Hong Zhou; Bao-xue Yang
Journal:  Acta Pharmacol Sin       Date:  2011-06       Impact factor: 6.150

7.  Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis.

Authors:  Vinita Takiar; Saori Nishio; Patricia Seo-Mayer; J Darwin King; Hui Li; Li Zhang; Anil Karihaloo; Kenneth R Hallows; Stefan Somlo; Michael J Caplan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-24       Impact factor: 11.205

Review 8.  Novel therapeutic approaches to autosomal dominant polycystic kidney disease.

Authors:  Wells B LaRiviere; Maria V Irazabal; Vicente E Torres
Journal:  Transl Res       Date:  2014-11-13       Impact factor: 7.012

9.  Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease.

Authors:  Baoxue Yang; Nitin D Sonawane; Dan Zhao; Stefan Somlo; A S Verkman
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

Review 10.  CFTR inhibitors.

Authors:  Alan S Verkman; David Synder; Lukmanee Tradtrantip; Jay R Thiagarajah; Marc O Anderson
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.